Generated by AI
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Its current commercial focus centers on DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through central venous catheters. The company serves healthcare providers and dialysis settings, where preventing bloodstream infections is a critical part of patient care. CorMedix also operates as a specialty pharmaceutical business with a product portfolio aimed at acute care markets and other medically important settings. Headquartered in Berkeley Heights, New Jersey, CorMedix Inc. plays a targeted role in the healthcare market by addressing complications associated with vascular access and chronic kidney failure treatment.
Website300 Connell Drive
Berkeley Heights, NJ, 07922
United States
The latest articles about CRMD.
Summary of Nov 19's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Feb 11's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about CRMD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.